Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study

Burghaus S, Drazic P, Wölfler M, Mechsner S, Zeppernick M, Meinhold-Heerlein I, Mueller MD, Rothmund R, Vigano P, Becker CM, Zondervan KT, Beckmann M, Fasching P, Berner-Gatz S, Grünewald FS, Hund M, Kastner P, Klammer M, Laubender RP, Wegmeyer H, Wienhues-Thelen UH, Renner S (2023)

Publication Type: Journal article

Publication year: 2023

Journal

DOI: 10.1002/ijgo.15062

Abstract

Objective: To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014–April 2018). Methods: This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-based biomarker immunoassays in samples from 919 women (aged 18–45 years) with suspicion of endometriosis and/or adenomyosis versus symptomatic controls. Endometriosis was stratified by revised American Society for Reproductive Medicine stage. Symptomatic controls were “pathologic symptomatic controls” or “pathology-free symptomatic controls”. The main outcome measure was receiver operating characteristic-area under the curve (ROC-AUC) and Wilcoxon P values corrected for multiple testing (q values). Results: CA-125 performed best in “all endometriosis cases” versus “all symptomatic controls” (AUC 0.645, 95% confidence interval [CI] 0.600–0.690, q < 0.001) and increased (P < 0.001) with disease stage. In “all endometriosis cases” versus “pathology-free symptomatic controls”, S100-A12 performed best (AUC 0.692, 95% CI 0.614–0.769, q = 0.001) followed by CA-125 (AUC 0.649, 95% CI 0.569–0.729, q = 0.021). In “adenomyosis only cases” versus “symptomatic controls” or “pathology-free symptomatic controls”, respectively, the top-performing biomarkers were sFRP-4 (AUC 0.615, 95% CI 0.551–0.678, q = 0.045) and S100-A12 (AUC 0.701, 95% CI 0.611–0.792, q = 0.004). Conclusion: This study concluded that no biomarkers tested could diagnose or rule out endometriosis/adenomyosis with high certainty.

Authors with CRIS profile

Involved external institutions

University of Oxford United Kingdom (GB) Roche Diagnostics GmbH Germany (DE) Ammerland Klinik GmbH Germany (DE) Medizinische Universität Graz Austria (AT) Charité - Universitätsmedizin Berlin Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Inselspital, Universitätsspital Bern Switzerland (CH) Universitätsklinikum Tübingen Germany (DE) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) Italy (IT) Roche Diagnostics (Schweiz) AG Switzerland (CH)

How to cite

APA:

Burghaus, S., Drazic, P., Wölfler, M., Mechsner, S., Zeppernick, M., Meinhold-Heerlein, I.,... Renner, S. (2023). Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15062

MLA:

Burghaus, Stefanie, et al. "Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study." International Journal of Gynecology & Obstetrics (2023).

BibTeX: Download